Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Kathy B. Baumgartner, Stephanie D. Boone, Yunfeng Cao, Avonne E. Connor, Kala Visvanathan, Richard N. Baumgartner
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-8 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Physical activity is recommended for most cancer patients as a nonpharmacological therapy to improve prognosis. Few studies have investigated the association between physical activity and breast cancer prognosis by ethnicity, biological, and modifiab
Autor:
Andrew R. Green, David L Goode, Simone M Rowley, Jia-Min Pang, Kylie L. Gorringe, Ian G. Campbell, Tanjina Kader, Dane Cheasley, Emad A. Rakha, Prue Hill, G. Bruce Mann, Kenneth Elder, Niko Thio, Stephen B. Fox, David J Byrne, Timothy Semple, Islam M. Miligy, Magnus Zethoven
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-13 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Intraductal papillomas (IDP) are challenging breast findings because of their variable risk of progression to malignancy. The molecular events driving IDP development and genomic features of malignant progression are poorly understood. In this study,
Autor:
Giuseppe Curigliano, Antonio Marra
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-9 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II
Autor:
Lauren Hale, Michelle J. Naughton, Tracy E. Crane, Electra D. Paskett, Michael L. Pennell, Gregory S. Young, Kathy Pan, Randi E. Foraker, Chloe Beverly, Elizabeth M. Cespedes Feliciano, Suzanne C. Danhauer
Publikováno v:
npj Breast Cancer, Vol 4, Iss 1, Pp 1-7 (2018)
NPJ Breast Cancer
NPJ Breast Cancer
Breast cancer survivors frequently report sleep problems, but little research has studied sleep patterns longitudinally. We examined trends in sleep quality and duration up to 15 years before and 20 years after a diagnosis of breast cancer, over time
Autor:
Justin M. Balko, Qiong Xu, Carlos R. Gil Del Alcazar, Yu Wang, Aditya Bardia, Vivian W. Wang, Rebecca Gelman, Hao Guo, Daniel G. Stover, Beth Overmoyer, Yaomin Xu, Maxwell R. Lloyd, Nan Lin, Eric P. Winer, Franziska Michor, Sara M. Tolaney, Kornelia Polyak, Jane E. Brock
Publikováno v:
npj Breast Cancer, Vol 4, Iss 1, Pp 1-9 (2018)
NPJ Breast Cancer
NPJ Breast Cancer
Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients wit
Autor:
Cecilia R. DeGraffinreid, Kevin Chu Foy, Electra D. Paskett, Maryam B. Lustberg, James L. Fisher, Darrell M. Gray
Publikováno v:
npj Breast Cancer, Vol 4, Iss 1, Pp 1-6 (2018)
NPJ Breast Cancer
NPJ Breast Cancer
African American (AA) women have a 42% higher breast cancer death rate compared to white women despite recent advancements in management of the disease. We examined racial differences in clinical and tumor characteristics, treatment and survival in p
Autor:
Fengmin Zhao, Joseph A. Sparano, Kathy D. Miller, Amye J. Tevaarwerk, Robert Gray, Lynne I. Wagner, Roisin M. Connolly, Sri Lakshmi Hyndavi Yeruva
Publikováno v:
npj Breast Cancer, Vol 4, Iss 1, Pp 1-5 (2018)
NPJ Breast Cancer
NPJ Breast Cancer
Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expr
Autor:
S. L. Moulder, Ravi Murthy, Elizabeth A. Mittendorf, David Ramirez, GB Mills, Alastair M. Thompson, KR Hess, Marion E. Scoggins, Thorunn Helgason, V. Valero, Banu Arun, Carlos H. Barcenas, Gary J. Whitman, Beatriz E. Adrada, J. Schwartz Gomez, Jennifer K. Litton, Helen Piwnica-Worms
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-6 (2017)
This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutat
Autor:
Bernard Rosner, Rulla M. Tamimi, Hannah Oh, Walter C. Willett, Stuart J. Schnitt, A. Heather Eliassen, Laura C. Collins, Laleh Montaser-Kouhsari, Andrew H. Beck, James L. Connolly
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-8 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
Studies have suggested that hormone receptor and Ki67 expression in normal breast tissue are associated with subsequent breast cancer risk. We examined the associations of breast cancer risk factors with estrogen receptor (ER), progesterone receptor
Autor:
Judith O. Hopkins, William T. Barry, Cynthia A. Thomson, Patty Spears, Eric P. Winer, Pamela J. Goodwin, Electra D. Paskett, Catherine M. Alfano, Melinda L. Irwin, Clifford A. Hudis, Dawn L. Hershman, Marian L. Neuhouser, Linda M. Delahanty, Elizabeth S. Frank, Jennifer A. Ligibel, Olwen Hahn, Thomas A. Wadden, Vered Stearns, Vanessa Bernstein, Julia White
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
Excess body weight is a poor prognostic factor in women with early breast cancer, but the effect of weight loss on the risk of breast cancer recurrence and mortality in women who are overweight or obese at the time of breast cancer diagnosis has not